{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:16:04Z","timestamp":1792631764529,"version":"4.5.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA) strains are major pathogens causing infections of the skin and soft tissues and more serious, life-threatening diseases, including sepsis and necrotizing pneumonia. The\n            <jats:italic>vraSR<\/jats:italic>\n            operon encodes the key regulatory system that modulates the stress response of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            elicited upon exposure to cell wall antibiotics. Mutation of\n            <jats:italic>vraS<\/jats:italic>\n            and\n            <jats:italic>vraR<\/jats:italic>\n            results in decreased oxacillin resistance\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">in vitro<\/jats:named-content>\n            . We investigated the effect of oxacillin treatment in experimental models employing a clinical USA300 MRSA strain (strain 923) and an isogenic\n            <jats:italic>vraSR<\/jats:italic>\n            deletion mutant (strain 923-M23). In a murine model of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            necrotizing pneumonia, animals were treated with oxacillin, beginning 15 min after inoculation. Among mice infected with mutant strain 923-M23, oxacillin treatment significantly improved survival compared with saline treatment, whereas oxacillin treatment had no effect in mice infected with strain 923. Similarly, treatment with oxacillin decreased the bacterial burden among animals infected with strain 923-M23 but not among animals infected with strain 923. In a murine skin infection model, oxacillin eliminated the development of dermonecrosis among 923-M23-infected mice and decreased the bacterial burden in the lesions, but not among strain 923-infected mice. We conclude that deletion of the\n            <jats:italic>vraSR<\/jats:italic>\n            operon allowed an oxacillin regimen to be effective in murine models of MRSA pneumonia and skin infection. These findings provide proof-of-principle for development of a new antibiotic that could restore the usefulness of oxacillin against MRSA by inhibiting VraS or VraR.\n          <\/jats:p>","DOI":"10.1128\/aac.01704-10","type":"journal-article","created":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T07:04:54Z","timestamp":1299567894000},"page":"2818-2823","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":35,"title":["Improved Oxacillin Treatment Outcomes in Experimental Skin and Lung Infection by a Methicillin-Resistant Staphylococcus aureus Isolate with a\n            <i>vraSR<\/i>\n            Operon Deletion"],"prefix":"10.1128","volume":"55","author":[{"given":"Dae Sun","family":"Jo","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Department of Pediatrics, The University of Chicago, Chicago, Illinois 60637"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Section of Critical Care Medicine, Department of Pediatrics, The University of Chicago, Chicago, Illinois 60637"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohui","family":"Yin","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Pediatrics, The University of Chicago, Chicago, Illinois 60637"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Boyle-Vavra","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Pediatrics, The University of Chicago, Chicago, Illinois 60637"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Daum","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Pediatrics, The University of Chicago, Chicago, Illinois 60637"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.70.11.6887-6891.2004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1990.tb03997.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.39.1.97"},{"key":"e_1_3_2_5_2","unstructured":"Baxter Healthcare Corp. 3 November 2010 accession date. Oxacillin (oxacillin sodium) injection solution. Baxter Healthcare Corp. Deerfield IL. http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=4055."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1028-1036.2003"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2006.00384.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.4.781"},{"key":"e_1_3_2_9_2","volume-title":"CLSI M100-S17","author":"Clinical and Laboratory Standards Institute","year":"2007","unstructured":"Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp070747"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00081-09"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043252"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-06"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/652237"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1323-1336.2001"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5219.124-a"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.185.18.5465-5472.2003"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1970.00310040109013"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/305709a0"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2003.03599.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(91)90399-V"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390806"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.183.23.6862-6868.2001"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/590157"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00256-09"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015177"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055356"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191260798"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/am.19.4.573-579.1970"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1009.040069"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.26426-0"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.336-343.2006"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01704-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01704-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:35:23Z","timestamp":1645486523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01704-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1128\/AAC.01704-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.01704-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"2010-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-02-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-05-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}